drugset / Trial / NCT06933056
Comparison of Antiplatelet Effects of Sotagliflozin to FDA-approved Antiplatelet Drugs
NaSingle-groupOpen-labelPrevention
Summary
This study will identify the potential benefits of regulating platelet activation with sotagliflozin compared to other FDA-approved drugs known to limit platelet activation.
Timeline
- Start
- 2025-09-02
- Primary completion
- 2026-09
- Completion
- 2026-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Apixaban | Small molecule | 5 mg | Oral |
| Subject | Aspirin | Small molecule | 81 mg | — |
| Subject | Clopidogrel | Small molecule | 75 mg | — |
| Subject | Sotagliflozin | Small molecule | 400 mg | — |
Indications
No indication recorded.